Radiopharmaceutical

Events

Partner Content

Targeted Radiopharmaceuticals Summit US (TRP US)

The inaugural Targeted Radiopharmaceuticals Summit US will bring together a worldwide community of specialists to address long-standing challenges in radiopharmac

News

Manufacturing foul-up hits Novartis' radioligand business

Novartis has shut down production of its radioligand therapies – one of its key

News

UK grants early access to Novartis' prostate cancer radiolig...

The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis' Advanced Accelerator Applications (AAA) subsidiary wh

News

Novartis gets first OK for radioligand Pluvicto in prostate ...

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radiolig

News

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development.

News

Bayer props up sagging radionuclide business with Noria acqu...

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofig

Targeted Radiopharmaceuticals Summit US (TRP US)

Manufacturing foul-up hits Novartis' radioligand business

UK grants early access to Novartis' prostate cancer radiolig...

Novartis gets first OK for radioligand Pluvicto in prostate ...

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Bayer props up sagging radionuclide business with Noria acqu...

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Radiopharmaceutical

Editor's Picks